Kymera Therapeutics (KYMR) Income towards Parent Company (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Income towards Parent Company of -$494.8 million for Q1 2026, down 151.9% year-over-year from $953.3 million in Q1 2025, and down 405.39% quarter-over-quarter from -$97.9 million in Q4 2025.
Kymera Therapeutics (KYMR) Income towards Parent Company (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Income towards Parent Company for 8 consecutive years, with -$494.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income towards Parent Company fell 151.9% year-over-year to -$494.8 million; the TTM figure through Mar 2026 stood at -$1.2 billion (down 90.29% YoY), while the FY2025 annual figure was -$749.9 million, down 50.63% from the prior year.
- Income towards Parent Company retreated to -$494.8 million in Q1 2026 per KYMR's latest filing, from -$97.9 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$38.7 million in Q4 2022 and bottomed at -$494.8 million in Q1 2026.
- Historically, Income towards Parent Company has averaged -$168.8 million across 5 years, with a median of -$166.9 million in 2023.
- Annual changes were most pronounced in 2022 — Income towards Parent Company soared 65.08% — and 2026, when it tumbled 151.9%.
- Kymera Therapeutics' Income towards Parent Company stood at -$38.7 million in 2022, then slumped by 78.16% to -$68.9 million in 2023, then retreated by 17.17% to -$80.8 million in 2024, then declined by 21.2% to -$97.9 million in 2025, then tumbled by 405.39% to -$494.8 million in 2026.
- Business Quant data shows KYMR's Income towards Parent Company at -$494.8 million in Q1 2026, -$97.9 million in Q4 2025, and -$342.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -729.42 Mn |
| Mar 31, 2026 | -494.75 Mn |
| Dec 31, 2025 | -97.90 Mn |
| Sep 30, 2025 | -342.58 Mn |
| Jun 30, 2025 | -218.80 Mn |
| Mar 31, 2025 | -196.41 Mn |
| Dec 31, 2024 | -80.77 Mn |
| Sep 30, 2024 | -221.31 Mn |
| Jun 30, 2024 | -107.96 Mn |
| Mar 31, 2024 | -189.04 Mn |
| Dec 31, 2023 | -68.93 Mn |
| Sep 30, 2023 | -185.39 Mn |
| Jun 30, 2023 | -166.93 Mn |
| Mar 31, 2023 | -112.45 Mn |
| Dec 31, 2022 | -38.69 Mn |
| Sep 30, 2022 | -94.40 Mn |
| Jun 30, 2022 | -85.35 Mn |
| Mar 31, 2022 | -168.49 Mn |
| Dec 31, 2021 | -34.03 Mn |
| Sep 30, 2021 | -270.29 Mn |